LaserSight moves to Nasdaq SmallCap:
This article was originally published in Clinica
Executive Summary
Laser vision correction company LaserSight is no longer eligible for trading on the Nasdaq National Market and its stock was transferred to the Nasdaq SmallCap Market from August 9. Continued listing on the SmallCap requires that the company's shares close at $1 on or before August 13. It may, however, be eligible for a 180-day grace period if it can demonstrate shareholders' equity of at least $5m, is in compliance with all other requirements and files an application for a new listing and related review. The Winter Park, Florida-based company believes it meets the requirements and intends to file the application on time.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.